Few Patients with KRAS-Mutated Tumors Receive Targeted Treatment

According to a recent study conducted by the Phase 1 Unit at the Department of Oncology, Copenhagen University Hospital, over 80% of solid tumors with KRAS mutations were found to have potentially targetable co-alterations. However, the study also revealed that less than 8% of patients with these tumors received treatment based on these findings.